Metabolics Pharma
Clinical-stage biopharmaceutical company developing centrally acting small-molecule therapies for metabolic diseases. The organization's lead candidate is a subcutaneously administered, centrally acting aminosterol that inhibits Protein Tyrosine Phosphatase 1B (PTP1B) and is being developed for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The company conducts preclinical in vivo metabolic disease studies and first-in-human clinical trials and has reported Phase 1a top-line safety and preliminary efficacy trends.
Industries
Nr. of Employees
small (1-50)
Products
ENT-03
Clinical-stage, centrally acting small-molecule candidate with PTP1B inhibitory activity intended to increase insulin sensitivity, lower blood glucose, and induce weight loss. Administered subcutaneously and evaluated in preclinical metabolic disease models and Phase 1a clinical trials.
ENT-03
Clinical-stage, centrally acting small-molecule candidate with PTP1B inhibitory activity intended to increase insulin sensitivity, lower blood glucose, and induce weight loss. Administered subcutaneously and evaluated in preclinical metabolic disease models and Phase 1a clinical trials.
Expertise Areas
- Clinical trial management (Phase 1)
- Metabolic disease drug development (obesity, type 2 diabetes, MASH)
- In vivo pharmacology and translational studies
- Targeted small-molecule development (PTP1B)
Key Technologies
- PTP1B-targeted small-molecule pharmacology
- Centrally acting aminosterol molecules
- Diet-induced obesity (DIO) rodent models
- Subcutaneous drug delivery
News & Updates
Phase 1a randomized single-ascending-dose study reported safety and tolerability at all doses and positive trends for weight reduction and increased insulin sensitivity at higher doses.
Preclinical data demonstrating sustained weight loss and improvements in liver pathology in an animal model for obesity.
In vivo study comparing ENT-03 to semaglutide showed rapid glucose normalization, sustained weight loss after treatment cessation, reduced adiposity and improved liver function in a DIO mouse model.
Preclinical results showing improvements in MASH, sustained weight loss and improved insulin sensitivity compared with a GLP-1 receptor agonist in animal models.
Announcement of initiation of a first-in-human Phase 1 study of ENT-03 in obesity and type 2 diabetes.
Phase 1a randomized single-ascending-dose study reported safety and tolerability at all doses and positive trends for weight reduction and increased insulin sensitivity at higher doses.
Preclinical data demonstrating sustained weight loss and improvements in liver pathology in an animal model for obesity.
In vivo study comparing ENT-03 to semaglutide showed rapid glucose normalization, sustained weight loss after treatment cessation, reduced adiposity and improved liver function in a DIO mouse model.
Preclinical results showing improvements in MASH, sustained weight loss and improved insulin sensitivity compared with a GLP-1 receptor agonist in animal models.
Announcement of initiation of a first-in-human Phase 1 study of ENT-03 in obesity and type 2 diabetes.